Cancer / Oncology
Mabwell Secures China Clinical Trial Approval for First-in-Class LILRB4/CD3 Bispecific T-Cell Engager in Blood Cancers
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...
June 25, 2026 | News
China Approves World's First CAR-T Therapy for Solid Tumours
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...
June 24, 2026 | News
Sonire Lands Major Japanese Government Backing to Advance Next-Generation Cancer Ultrasound Therapy
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therapeut...
June 19, 2026 | News
10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms 10x...
June 19, 2026 | News
Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer
Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...
June 17, 2026 | News
Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data
Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...
June 15, 2026 | News
Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis
Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...
June 15, 2026 | News
Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...
June 12, 2026 | News
Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
June 12, 2026 | News
China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours
Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...
June 10, 2026 | News
Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours
NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...
June 08, 2026 | News
Innovent's Arcotatug Tavatecan Meets Phase 3 Endpoint in Advanced Gastric Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
June 05, 2026 | News
ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer
ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...
June 02, 2026 | News
Pfizer And Innovent Biologics Forge Global Oncology Alliance Covering 12 Cancer Programs
Pfizer Inc. and Innovent Biologics, Inc. announced the companies have entered into a strategic global licensing and collaboration agreement for the r...
June 01, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
